Hook / Thesis
Relay Therapeutics is no longer just a company selling promise about computational drug discovery. The clinical readouts for zovegalisib (RLY-2608) over the past six months have shifted the narrative: the drug is delivering meaningful efficacy signals with a tolerability profile compatible with chronic dosing, and the team is rapidly expanding indications and combinations. That combination - efficacy, tolerability, and a partner-supplied CDK4/6 inhibitor for combination trials - makes zovegalisib look like a platform in disguise. For active traders, that repositioning creates a tradeable long with explicit entry, target and stop parameters.
Why the market should care
PI3Kα inhibitors have a long history of efficacy in PIK3CA-driven disease but have been hamstrung by toxicity when used chronically. Zovegalisib's recent Phase 2 data in PIK3CA-driven vascular anomalies delivered a 60% volumetric response at 12 weeks and clinical improvement in 89% of patients by investigator assessment, with no discontinuations for adverse events. That reads as differentiated safety and supports chronic use in benign but morbid conditions - a large unmet need with limited drug options. In oncology, the 44% objective response rate reported for the zovegalisib + atirmociclib + endocrine therapy triplet in heavily pre-treated metastatic breast cancer is notable for a company of Relay's size; it justified a Phase 3 plan in frontline disease and a supply agreement with Pfizer for atirmociclib.
Business snapshot
Relay builds drugs using its Dynamo computational/experimental discovery platform. That platform produced zovegalisib, a selective PI3Kα inhibitor now in Phase 3 for HR+/HER2- metastatic breast cancer and in development for PIK3CA-driven vascular anomalies. The market is already adjusting: Relay's market capitalization is about $2.31B, the 52-week high is $17.32 and the low is $2.75. Recent trading shows volatility and heightened interest - average daily volume sits in the ~3.2M range (2-week average ~4.3M in the snapshot), and short interest remains sizable, which can amplify moves in either direction.
Why zovegalisib could be a platform in disguise
- Zovegalisib is being tested across mechanistically-related but clinically distinct indications (oncology and vascular anomalies). Success in both chronic benign disease and cancer suggests a therapeutic window that can support multiple programs and chronic dosing.
- Combination data with Pfizer's atirmociclib produced a 44% ORR in heavily pretreated metastatic breast cancer and is being positioned for a Phase 3 frontline trial. Having a partner-supplied CDK4/6 inhibitor removes a major operational barrier for Relay and materially de-risks combination execution.
- Regulatory momentum: zovegalisib has received Breakthrough Therapy designation for breast cancer, which shortens regulatory timelines and attracts investor focus ahead of pivotal readouts.
Support from the numbers
- Market cap: $2.31B - positions Relay as a mid-cap clinical-stage biotech with enough market value to sustain visibility but still dependent on clinical execution.
- Cash metric in the snapshot reads $6.88 (per share metric reported), enterprise value roughly $2.11B and free cash flow was negative -$213.38M, signaling ongoing spend to advance trials.
- Operating leverage: EPS is negative (-$1.42) and price-to-sales is artificially high at 217x due to minimal current revenues, underscoring that valuation must be judged on pipeline outcomes rather than current sales.
- Trading/technical setup: the stock pulled back from a $17.32 52-week high to ~$12.04 today, RSI ~40 and MACD showing bearish momentum. Heavy short volumes and recent spikes in short volume (e.g., May 19 short volume >5.3M shares) mean a positive clinical update could trigger rapid re-rating; conversely, bad news can accelerate sell-offs.
Valuation framing
Relay is a classic binary-value security: intrinsic cash flows are negative and the balance sheet supports trials only for so long. The $2.31B market cap is effectively a forward bet on zovegalisib becoming an approved therapy across one or more indications and on the Dynamo platform producing follow-on assets. With no meaningful revenue today and EPS of -$1.42, traditional multiples (P/E, P/S) are not helpful. Instead, valuation should be viewed relative to potential market access: if zovegalisib reaches the market in breast cancer and captures a modest share, the stock can justify a multi-bagger from here; if clinical or regulatory setbacks occur, the valuation will compress quickly back toward cash-adjusted enterprise value. The technical picture also supports a trade: a move back toward the prior high ($17.32) is a reasonable near-to-mid-term target if upcoming catalysts continue to surprise positively.
Catalysts to watch
- Ongoing expansion cohorts and dosing data in PIK3CA-driven vascular anomalies (400mg once daily and 300mg twice daily cohorts recently opened) - early readouts of durability and safety will be market moving.
- Phase 3 start and design details for the frontline metastatic breast cancer study with atirmociclib - protocol details, enrollment timelines and interim analyses could drive re-rating.
- Any additional regulatory updates related to Breakthrough Therapy interactions with the FDA or rolling submissions - faster pathways or guidance can compress the time to value.
- Quarterly financials and cash burn updates - given a negative free cash flow of -$213.4M, periodic funding commentary will influence sentiment and dilution expectations.
Trade plan (actionable)
My actionable trade: initiate a long position in RLAY with defined risk controls and a multi-month horizon to ride clinical and regulatory catalysts.
| Entry | Target | Stop | Horizon |
|---|---|---|---|
| $12.10 | $18.00 | $9.50 | long term (180 trading days) |
Rationale: $12.10 is the recent close and offers an entry near the current trading level; $18.00 is above the 52-week high of $17.32 and represents a re-rating driven by positive Phase 3/Phase 2 readouts or a meaningful regulatory win. The stop at $9.50 cuts exposure if the program or safety narrative deteriorates materially. I favor a long term (180 trading days) horizon because the meaningful catalysts (Phase 3 initiation, cohort readouts and regulatory interactions) will unfold over months, not days.
Position sizing and risk controls
Keep exposure limited to a small percentage of liquid risk capital. Given the stock's volatility, use the stop and reassess on a successful test of momentum above $14.50; consider scaling out partial positions at $14–15 on intraday strength to de-risk the remainder ahead of a pivotal announcement.
Risks (balanced view)
- Clinical risk: Phase 3 or later-stage readouts can fail or under-deliver vs. early small-cohort signals. While Phase 2 and expansion cohort data are encouraging, they are not guarantees of Phase 3 success.
- Tolerability and long-term safety: early tolerability is promising, but chronic dosing across larger populations can reveal rare adverse events that erode the therapeutic window and commercial viability.
- Cash runway and dilution: negative free cash flow (~-$213M) and ongoing development costs mean Relay could need to raise capital; equity raises would dilute current holders and pressure the stock.
- Competitive dynamics and class risk: other PI3Kα inhibitors or alternative targeted therapies could capture market share or yield superior efficacy/tolerability, compressing Relay's addressable market.
- Market structure risk: high short interest and concentrated float can produce exaggerated moves in both directions, increasing execution risk for this trade.
Counterargument to the thesis
One reasonable counterargument: early signal-seeking cohorts often overestimate eventual population-level benefit. The vascular anomaly and triplet data sets are relatively small and may reflect selection bias or investigator assessment uplift that does not translate into robust regulatory endpoints. If Phase 3 fails to replicate those effect sizes or if new safety signals emerge with broader exposure, the “platform” thesis collapses and the valuation reverts quickly. That outcome would argue for either not initiating or cutting the trade at the stop described above.
What would change my mind
I would reduce conviction if: (a) updated safety data from expansion cohorts show emerging chronic toxicities, (b) cash guidance implies an imminent dilutive raise without milestones that de-risk Phase 3 timelines, or (c) enrollment or design setbacks delay the Phase 3 program materially. Conversely, my view would strengthen if interim Phase 3 endpoints or registrational-friendly biomarker data arrive ahead of schedule, or if commercial partnership terms expand beyond supply agreements into co-development or commercialization in large markets.
Conclusion
Relay has moved from being a platform story to one where a single asset, zovegalisib, is pulling the company into multiple therapeutic baskets. That transition is precisely why the stock is tradeable: the upside from successful readouts is asymmetric relative to the downside if the company can demonstrate safety + efficacy in larger cohorts and maintain execution on Phase 3 development. The plan above offers a clear entry, stop and target and a 180-trading-day horizon designed to capture the next wave of clinical and regulatory catalysts while protecting capital if the story breaks the wrong way.
Key near-term dates to track: expansion cohort readouts for vascular anomalies, Phase 3 start details and the company's next financial update for cash burn and guidance.